Renal Cell Carcinoma Clinical Trials
2 recruiting
Showing 1–14 of 14 trials
Recruiting
Phase 1Phase 2
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
MelanomaNon-small Cell Lung CancerSquamous Cell Carcinoma (Skin)+2 more
AstraZeneca60 enrolled11 locationsNCT07115043
Recruiting
DESTINY-PANTUMOUR04
Liver CancerEsophageal CancerPancreatic Cancer+24 more
AstraZeneca100 enrolled15 locationsNCT07124000
Recruiting
Phase 1
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
MelanomaNon-small Cell Lung CancerRenal Cell Carcinoma
Shanghai Henlius Biotech174 enrolled69 locationsNCT07160335
Recruiting
Not Applicable
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy
Breast CarcinomaMelanomaNon-small Cell Lung Cancer+4 more
Wake Forest University Health Sciences244 enrolled39 locationsNCT05703269
Recruiting
Phase 2
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Breast CarcinomaUrothelial CarcinomaOvarian Carcinoma+26 more
Mayo Clinic27 enrolled1 locationNCT07285044
Recruiting
Phase 2
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Renal Cell Carcinoma
Diwakar Davar480 enrolled1 locationNCT07223424
Recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Bladder CarcinomaEsophageal CarcinomaNon-small Cell Lung Cancer+13 more
Guardant Health, Inc.2,020 enrolled57 locationsNCT05059444
Recruiting
Not Applicable
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
Breast CancerOvarian CancerEndometrial Cancer+6 more
University of California, San Francisco1,000 enrolled1 locationNCT05056077
Recruiting
Phase 3
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Head and Neck CancerRenal Cell CarcinomaLung Cancer Metastatic
UNICANCER646 enrolled40 locationsNCT05078047
Recruiting
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
Breast CancerMelanomaSquamous Cell Carcinoma of Head and Neck+4 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano1,000 enrolled1 locationNCT05621837
Recruiting
Phase 1Phase 2
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
MelanomaCancerSolid Tumor+1 more
Simcha IL-18, Inc.316 enrolled6 locationsNCT04787042
Recruiting
Phase 1
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Breast CancerOvarian CancerProstate Cancer+6 more
Nammi Therapeutics Inc100 enrolled8 locationsNCT06582017
Recruiting
The Optimal Number of Fiducial Marker for Stereotactic Body Radiotherapy
Liver CancerPancreatic CancerLung Cancer+1 more
Peking University Third Hospital57 enrolled1 locationNCT06342323
Recruiting
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
Triple-Negative Breast CancerRenal Cell CarcinomaNon-Small-Cell Lung Carcinoma+1 more
VastBiome800 enrolled1 locationNCT05037825